Health-related Quality of Life and hospital costs of Finnish melanoma patients participating in the second Multicenter Selective Lymphadenectomy Trial (MSLT-II)
This study suggests that undergoing CLND after a positive SLN biopsy is not a predictor of worse HRQoL. CLND generates greater costs initially, but there seem to be no major differences in total cost per patient between the two groups.
Authors
- Pia Heino (ORCID: https://orcid.org/0000-0003-0024-1915)
- John F. Thompson (ORCID: https://orcid.org/0000-0002-2816-2496)
- Tiina Jahkola (ORCID: https://orcid.org/0000-0002-9123-865X)
- Micaela Hernberg (ORCID: https://orcid.org/0000-0002-0139-4596)
- Jukka Pappinen (ORCID: https://orcid.org/0000-0002-1174-8669)
- Mark B. Faries (ORCID: https://orcid.org/0000-0003-1752-7282)
Institutions
- Cedars-Sinai Medical Center (US)
- The University of Sydney (AU)
- University of Helsinki (FI)
- Helsinki University Hospital (FI)
- Angeles Clinic and Research Institute (US)
Publication Details
- Journal
- Acta Oncologica
- Published
- 2025-02-10
- DOI
- https://doi.org/10.2340/1651-226x.2025.42314
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health